



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

March 07, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Submission of Investor Presentation for the Arihant Capital “Bharat Connect Conference- Rising Stars 2026”**

Ref.: SEBI Master Circular: HO/49/14/14(7)2025CFD-POD2/1/3762/2026 dated 30th January 2026

SYMBOL: ANONDITA

ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, we hereby submit the Investor presentation to be made at the Bharat Connect Conference- Rising Stars 2026, organized by Arihant Capital, scheduled to be held on 9th March 2026.

The said presentation will also uploaded on the website of the Company: <https://anonditamedicare.com/>.

Kindly take the above information on your record.

Thanking You.
Yours faithfully,

For and on behalf of
ANONDITA MEDICARE LIMITED

Bhawna Bisht
Company Secretary and Compliance Officer
M No : A70843



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com | accounts@anonditahealthcare.com
Website: www.anonditamedicare.com



Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Investor Presentation

Safe Harbour Statement

This presentation and its accompanying materials (collectively, the "Presentation") have been prepared by Anondita Medicare Limited ("Anondita," "the Company," or "we") for informational and discussion purposes only. This Presentation does not constitute an offer to sell or solicitation of an offer to purchase any securities, investment advice, or recommendation, nor should it be relied upon as the basis for any investment decision or contractual commitment. Any securities offering by the Company will be made exclusively through formal offering documents containing complete information about the Company, its business, and associated risks.

While the information contained herein has been compiled from sources the Company believes to be reliable, the Company makes no representations or warranties, express or implied, regarding the accuracy, completeness, or fairness of the information presented. This Presentation may not include all material information concerning the Company, and any reliance on this information is entirely at the recipient's own risk. The Company expressly disclaims all liability for any errors, omissions, or inaccuracies contained herein.

This Presentation contains forward-looking statements concerning the Company's business prospects, market opportunities, and strategic outlook based on current expectations and assumptions. These statements are subject to significant risks and uncertainties, and actual results may differ materially from those expressed or implied. Various factors may cause actual outcomes to vary, including economic conditions in India and internationally, industry trends and competitive dynamics, execution of business strategies, technological developments, revenue variability, market acceptance, regulatory changes, and other business risks. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Any forward-looking statements, projections, or opinions attributed to third parties included in this Presentation are not endorsed by the Company, and the Company assumes no responsibility for their accuracy or reliability. By reviewing this Presentation, recipients acknowledge that they have read, understood, and agree to be bound by the terms of this disclaimer.

About Anondita Medicare Limited

Anondita Medicare Limited, is an Indian manufacturer of **male and female condoms**, operating under its flagship brand “**COBRA.**” The company runs its own manufacturing facility and follows a quality-driven, compliant production model.

The company is led by **Mr. Anupam Ghosh, Managing Director and Promoter**, who brings over **25 years of experience** in the healthcare and contraceptive products industry. His deep domain expertise, entrepreneurial background, and execution capability provide strong leadership and strategic direction to the company.

With a strong domestic presence, particularly in **North India**, Anondita Medicare is actively **expanding its geographical footprint** across India and international markets. Ongoing initiatives such as **UN qualification, automation-led capacity enhancement, and patented female condom products** position the company for scalable growth and long-term value creation.



MISSION ROADMAP

2026

Addition of manufacturing facilities for female latex condoms.

2027

Commencement of female latex condom manufacturing.

2028

Addition of facilities and commencement of manufacturing for male and female non-latex condoms.

2029

Launch of latex plantation initiative to enable in-house raw material sourcing and enhance long-term cost efficiency.

2030

Diversification into medicines and surgical healthcare products.

VISION

Anondita Medicare Ltd. aspires to be a leading force in the fight against HIV/AIDS and the prevention of unintended pregnancies by delivering safe, reliable, and high-quality sexual health and personal wellness products. With a strong focus on innovation and excellence, the Company aims to broaden its product portfolio, expand its footprint in domestic and global markets, and establish itself as a trusted name in global healthcare.



Key Facts & Figures

30+
Years of Experience

11
Manufacturing lines

81+
No. of Machinery

FY25
Revenue – 7,699.07
EBITDA – 2,565.22
PAT – 1,650.47

4
Installed New lines

280+
Team Size

H1 FY26
Revenue – 5409.70
EBITDA – 1920.14
PAT – 1301.78



Quality Assurance

- Stringent quality control processes
- Each and Every Condom is Electronically Tested
- ISO Certification (ISO - 9001; ISO 13485:2016)
- Bureau of Indian Standards (BIS) Of Company has been nominated for MSME Award 5000.
- Certificate of Good Manufacturing Practices (GMP)
 - Medical Device License (MD License)
 - WHO certification

Key Events And Milestones

01



1999

- The erstwhile proprietorship “M/s Health Care Products” was started by our current promoter,
- Mr. Anupam Ghosh for the packaging and sale of contraceptives and gloves.

02



2001-2010

- Started Marketing and Packaging in our brand by Purchasing condoms from TTK & JK.
- Established our own manufacturing Unit in Noida.
- Started our manufacturing by providing services to Mankind Pharma Ltd. For "ManForce" brand.
- Started supply of our product to ZVDUS.

03



2011-2015

- Got our factory approved by KFW Germany and got the India's first manufacturing unit order to supply to Government of Nepal.
- The proprietorship was renamed to “M/s Anondita Healthcare” in 2013
- Established a new state of art Unit In Noida with additional manufacturing facility.

04



2016-2018

- Got our 1st order from Government to supply NIRODH.
- We got certification from WHO GMP from Drug licensing and Controlling authority, Govt. of India.
- Got Business Awards for ANONDITA HEALTHCARE AS EMERGING HEALTHCARE COMPANY OF THE YEAR in the second edition of the Times Business Awards 2019, held at Roseate House, Aerocity, New Delhi.

05



2019

- Got mentioned In various articles in newspapers, newsletters, etc., and awards as a leading manufacturer of condoms and surgical gloves.
- Recognized by various articles in newspapers, newsletters, etc., on CSR Initiatives for welfare activities by the Anondita Healthcare.

06



2024

- Incorporation of our Company, Anondita Medicare Limited.
- Takeover of M/s Anondita Healthcare by our company vide Business Takeover Agreement dated April 01, 2024
- Our company acquired 100% shareholding in “Anondita Healthcare and Rubber Products India Limited” vide a Share Purchase Agreement dated April 01, 2024, entered into between Anondita Healthcare and Rubber Products India Limited (Formerly Anondita Healthcare and Rubber Products India Private Limited) (First Party), Mr. Reshant Ghosh and Ms. Sonia Ghosh (Second Party) and our Company (Third Party).

Establishment of the Brand “Cobra Condoms”



After years of supplying our products to top pharmaceutical companies, we have now entered the market with our subsidiary's brand - Cobra Condoms.

Key Highlights

Each and every condom is 100% electronically tested
Eye-catching designs and visuals
Export-quality packaging for superior presentation and safety

Previously Manufactured for Manforce

Our expertise includes producing condoms for Manforce, one of India's leading condom brands - a testament to our trusted quality and manufacturing excellence.

Now Producing Female Condoms

Responding to market needs, we have expanded our product line to include female condoms, empowering women with more contraceptive choices. We are the only company in India having a patent in universal for manufacturing female condoms.

Types of Condoms



01 Extra Large
Condoms

02 Ultra-Thin
Condoms

03 Dotted
Condoms

04 Multi-textured
Condoms

05 Extra Strong
Condoms

06 Plain
Condoms

07 Ribbed
Condoms

08 Female
Condoms

Exciting Flavors

01 Strawberry

02 Mint

03 Chocolate



04 Butterscotch

05 Coffee

06 Bubblegum

Manufacturing Facility

Enabling operational scale-up and future growth



Scaling Manufacturing Capabilities – Noida Facility



Approved ~1,360 million pieces per annum capacity expansion at the upcoming Noida manufacturing facility (additional unit)

Current vs Expanded Capacity

- **Existing installed capacity:** 869 million pieces per annum, 16 Manufacturing lines under WIP
- **Total incremental capacity planned:** ~1,360 million pieces per annum

Project Investment & Funding

Estimated project cost: ~₹75 crore

Funding mix:

- Internal accruals
- Debt

Focus on **financial discipline and operational leverage**

Receives SABS Certification for Male Condoms



- Received SABS certification for natural rubber latex male condoms
- Certification as per **SANS 4074:2017** standards
- Applies to **select COBRA brand variants**

Strategic Significance

- Enables access to **regulated export markets**
 - South Africa
 - Africa-focused tenders
- Strengthens credibility with:
 - Government bodies
 - NGOs
 - Institutional buyers
- Reinforces **compliance-driven manufacturing platform**
- Supports **long-term export-led growth**

MDSAP Certification Received Under ISO 13485:2016

Scope of Certification

Covers male and female condoms

Enables marketing across **five regulated international jurisdictions:**

- Australia
- Brazil
- Canada
- Japan
- United States of America

Strategic Importance

- Provides access to **highly regulated medical device markets**
- Enhances **regulatory credibility and global compliance standing**
- Strengthens the Company's **quality and audit framework**
- Supports **international expansion and export-led growth**



Anondita Medicare Limited is India's first company to receive MDSAP Certification, enabling single-audit regulatory compliance accepted globally. The certification is in accordance with ISO 13485:2016 and has been issued by DQS Medizinprodukte GmbH, a designated certification authority.

Certifications



FORM MD-9
[See sub-rule (1) rule 25]

Licence to Manufacture for Sale or for Distribution of Class C or Class D medical device

Licence Number: **MFG/MD/2024/000575**

1. M/s ANONDITA MEDICARE LIMITED, FLATNO. 704 NARMADA BLK,6,SEC-D,PKT-6 VASANT KUNJ ,NEW DELHI,NEW DELHI(Vasant Kunj), South West Delhi, Delhi (India) - 110070 Telephone No.: 8178391045 FAX: 0120-4520314 has been licensed to manufacture for sale or for distribution the below listed medical device(s) at the premises situated at M/s Anondita Medicare Limited, D-001, sector ,80, noida , G.B. Nagar, Gautam Buddha Nagar, Uttar Pradesh (India) - 201305 Telephone No.: 8178391045,09773510525 FAX: 0120-4520314

2. Details of medical device(s) [Annexure]

3. The names, qualifications and experience of the competent technical staff responsible for the manufacture and testing of the above mentioned medical device(s): **As per records maintain by the manufacturer**

4. This licence is subject to the provisions of the Medical Devices Rules, 2017 and conditions prescribed therein.

ANNEXURE

S.No.	Details Of Device(s)
1	<p>Generic Name:Natural Rubber Latex Male Condom (With drug Benzocaine 4.5% w/w) Model No.:Natural Rubber Latex Male Condom - (Dotted with drug Benzocaine)-in House ,Natural Rubber Latex Male Condom - (Multi Textured with drug Benzocaine)-in House ,Natural Rubber Latex Male Condom - (Plain with drug Benzocaine)-in House</p> <p>Intended Use:The intended use of condom to reduce the risk of transmission of HIV (AIDS) & many other sexually transmitted infections (STIs) during sexual intercourse. It is also used as contraceptive for prevention of pregnancy. It is for single use only. It enhance or extends the timing and intimacy of intimate moment.It prevents premature ejaculation.</p> <p>Class of medical device:Class C Material of construction:centrifuged latex Dimension(if any):Plain condoms usually have a length between minimum 170 mm and Dotted & Multi-textured condoms have a length of minimum 180 mm. Shelflife:3 Years Sterile or Non sterile:Non-Sterilized Brand Name(if registered under the Trade Marks Act, 1999):Cobra Extra Time Condom, ENJOY, MID NIGHT, VIGORE, FORCE, COBRA PREMIUM, PLAY NIGHT, LIV CHOICE, VICOGRA, FUNKEY, MENCOUR, 6XE FLIN, 6XE BUBBLE</p>
2	<p>Generic Name:Natural Rubber Latex Male Condom Model No.:Natural Rubber Latex Male Condom - (Dotted)-in House ,Natural Rubber Latex Male Condom - (Multi Textured)-in House ,Natural Rubber Latex Male Condom - (Plain)-in House</p> <p>Intended Use:The intended use of condom to reduce the risk of transmission of HIV (AIDS) & many other sexually transmitted infections (STIs) during sexual intercourse. It is also used as contraceptive for prevention of pregnancy. It is for single use only. It enhance or extends the timing and intimacy of intimate moment.It prevents premature ejaculation.</p> <p>Class of medical device:Class C Material of construction:Natural Rubber Latex Dimension(if any):Plain condoms usually have a length between minimum 170 mm and Dotted & Multi-textured condoms have a length of minimum 180 mm. Shelflife:3 Years Sterile or Non sterile:Non-Sterilized Brand Name(if registered under the Trade Marks Act, 1999):LOVE TIME, COBRA, ENJOY, MIDNIGHT, VIGORE, FORCE, COBRA PREMIUM, NIRODH, ASHA, STYLE, THRIL, DELUXE NIRODH, MITHUN, PLAY NIGHT, 6XE, LIV CHOICE, VICOGRA, FUNKEY, MENCOUR, LOVE FORCE, 6XE BUBBLE, M-FORCE ,AM PM, DARK HORSE, FIX GUARD</p>
3	<p>Generic Name:Natural Rubber Latex Condom- Female Model No.:NIL</p> <p>Intended Use:The intended use of condom to reduce the risk of transmission of HIV (AIDS) & many other sexually transmitted infections (STIs) during sexual intercourse. It is also used as contraceptive for prevention of pregnancy. It is for single use only. It enhance or extends the timing and intimacy of intimate moment.It prevents premature ejaculation.</p> <p>Class of medical device:Class C Material of construction:Natural Rubber Latex , USP Corn Starch Powder Dimension(if any):Female condom is a nitrile sheath or pouch 17 cm (6.7 in) in length Shelflife:3 Years Sterile or Non sterile:Non-Sterilized Brand Name(if registered under the Trade Marks Act, 1999):MIDNIGHT, COBRA PREMIUM</p>

Place: **RAJEEV SINGH RAGHUVANSHI**
Date:09-Aug-24
Central Licensing Authority

Management Overview



Mr. Anupam Ghosh

Managing Director & Promoter

With over **25 years of experience** in the healthcare products industry, Mr. Ghosh is the driving force behind the company's growth. He began his entrepreneurial journey in 1999 and established a condom manufacturing facility in 2004. He brings strong expertise in **strategic planning, product development, innovation, and business execution**, and currently leads the company's overall vision and expansion.



Mrs. Sonia Ghosh

Promoter

Mrs. Ghosh has over **10 years of experience** in administration and human resource management. She plays a key role in **execution, governance, and organizational development**, with a strong track record of managing administrative operations across group companies.



Mr. Reshant Ghosh

Whole Time Director & Promoter

Mr. Ghosh brings **3 years of experience in marketing and sales**, with strengths in market analysis, strategy execution, and distributor engagement. He has been instrumental in building a **nationwide distributor and retailer network**, enhancing product reach and driving sales growth.

Establishment of the Brand “Cobra Condoms”



ANONDITA MEDICARE LIMITED

1

Global Expansion

Scale exports beyond Africa into high-potential international markets.

2

UN qualification

In advanced stages, enabling access to global markets, with exports targeted to begin by end-FY26 or early next Q1FY26.

3

Automation & Efficiency

Enhance quality, scalability, and margins through advanced manufacturing.

4

Product Innovation

Launch patented female condoms to address underserved demand.

Strengths

Established condom manufacturer in India with **own brand and manufacturing facility**.

Strong demand driven by rising **STD awareness** and preventive healthcare adoption.


Well-recognized presence in North India with a diversified product portfolio.

Fully integrated in-house printing, packaging, and boxing—lower costs, minimal vendor dependency.

CNG biofuel operations—cost-efficient and environmentally superior to competitors.

Threats

Fluctuating latex prices, which may impact input costs and margins.



Weaknesses

Dependence on **latex raw material supply**, exposing the business to procurement and price volatility.


Advantage as one of the few manufacturers using **environmentally friendly fuels**.

Potential market opportunities arising from **industry consolidation**, including HLL Lifecare's divestment.


Opportunities

Growing shift toward **sustainable and eco-friendly manufacturing**.

Global Condom Market Outlook





Global Procurement & Donor Market (Volumes)



Regional Market Overview

- Asia Pacific (incl. SE Asia):** ~45–50% of global demand – largest & fastest-growing region driven by population scale, government programs, and rising retail penetration.
- North America (US):** High-value commercial market with premium pricing; retail-led demand and strong growth in non-latex and online sales.
- Europe:** Mature, stable market with high awareness and consistent replacement demand through pharmacies and modern trade.
- Latin America:** Mid-growth region led by Brazil & Mexico; mix of commercial sales and government/NGO programs.
- Africa:** Low retail value, very high unit volumes; demand largely fulfilled via donor-funded public health distribution.

Indian Condom Market Outlook



Based on Product Type:

- Male condoms dominate the Indian market with **over 95% share**, driven by significantly higher adoption than female condoms.
- Only **~8% of women** use condoms as a contraceptive method in India. Male condoms are also far more affordable, costing **~USD 0.12 per unit**, compared to **~USD 2.5 per unit** for female condoms.

By Material Type: Non-Latex Innovation Drives Premium Growth

- Latex products accounted for 80.45% of 2024 revenue due to their cost advantages. While latex maintains a substantial market share, non-latex alternatives are expected to grow at a 10.56% CAGR, driven by consumer demand for allergy-free products and enhanced sensation.

Source : [Condom Market, marknteladvisors, mordorintelligence](#)

Large youth population & demographic dividend

India has the world's largest youth cohort (15–29 years ~370–420M) and a low median age (~29). A large sexually active young cohort supports expanding demand for contraceptives and sexual wellness products.

Rising sexual-health awareness & government programs

NACO and state programs, plus NGOs, continue awareness campaigns (HIV/AIDS prevention, family planning). Awareness is high but consistent use lags — creating opportunity for behavior change marketing and product innovation.

E-commerce & quick commerce channels

expanding online shopping and quick commerce drastically improve discreet access and assortment (brands + SKUs). India's online shopper base already >270M and e-retail growth is accelerating — this supports premium, novelty, and niche condom SKUs selling directly to consumers. Cite Bain / IBEF / Euromonitor for e-commerce growth.

Urbanisation, rising disposable incomes and premiumisation


more consumers in urban / tier-2/3 cities willing to pay for flavored/premium/latex-alternative products and sexual well-being brands. Reports flag premiumisation as a key growth lever.

Supply-side capacity & institutional procurement

big public producers (HLL) plus large private players increase availability; procurement contracts with public health programs keep base volumes high, while private brands chase retail share and margin.

Stigma reduction & lifestyle shifts

changing social norms, greater openness among younger cohorts, and celebrity/marketing campaigns are reducing stigma — enabling private brands to advertise more and expand categories (sexual wellness bundles, lubricant + condom SKUs).




Sources: [Drishti IAS+1](#), [NACO+1](#), [Bain+2](#)India Brand Equity Foundation+2, [Grand View Research+1](#), [The Economic Times+1](#),

Financial Snapshot (Consolidated)


(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹


Revenue from Operations




EBITDA — EBITDA Margin



PAT — PAT Margin



EPS



Income Statement (Half Yearly) Consolidated

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	H1 FY26	H1 FY25	YoY Change
Revenue from operations	5,409.70	3,140.50	72%
Cost of Material Consumed	2,438.97	1,611.11	
Employee benefit expense	348.10	261.85	
Other Expenses	702.49	295.04	
Total	3,489.56	2,168.00	
EBITDA	1,920.14	972.50	97%
EBITDA Margin (%)	35.49%	30.97%	452 bps
Depreciation and amortization expense	40.87	36.27	
EBIT	1,879.27	936.23	101%
Financial costs	182.35	145.32	
Other Income	40.77	10.26	
PBT	1,737.69	801.17	117%
Tax Expense			
Current Tax	420.42	180.88	
Deferred Tax	15.49	17.30	
PAT	1,301.79	603.00	116%
Net Profit	1,301.79	603.00	116%
Net Profit Margin (%)	24.06%	19.20%	486 bps
EPS (Diluted)	9.12	6.16	48%

Balance sheet (Half Yearly) Consolidated

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Equities and Liabilities	H1 FY26	H1 FY25	Assets	H1 FY26	H1 FY24
Shareholder's Funds			Non-current Assets		
Share Capital	1,808.79	886.36	Fixed Assets	1,277.25	1,246.61
Reserves & Surplus	9,053.54	1,785.56	Goodwill	19.18	19.18
Minority Interest	134.39	87.01	Capital Work in progress	1,522.08	50.36
Total	10,996.72	2,758.93	Non Current Investment	331.40	331.40
Non-Current Liabilities			Deffered Tax Assets (Net)	0.22	0.16
Lont Term Borrowings	1,307.40	1,320.65	Long Term Loans & Advances	37.66	37.66
Deferred Tax Liability	24.06	17.30	Other Non Current Assets	0.24	0.38
Long Term Provisions	15.13	7.51	Total Non-current Assets	3,188.03	1,685.75
Total Non-Current Liabilities	1,346.59	1,345.46	Current Assets		
Current Liabilities			Inventories	1,450.10	951.05
Short Term Borrowings	1,773.29	1,475.52	Trade Receivables	4,809.67	1,907.55
Trade Payables			Cash & Bank Balance	3,650.96	79.67
outstanding Dues of micro & small Enterprises	153.00	249.54	Short Term Loans & Advances	2,127.18	1,551.85
outstanding Dues of Creditors	484.05	73.11	Other Current Assets	825.49	271.10
Other Current Liabilities	323.39	362.97	Total Current Assets	12,863.40	4,761.22
Short Term Provisions	974.38	181.44	Total	16,051.43	6,446.96
Total Current Liabilities	3,708.11	2,342.58			
Total	16,051.43	6,446.96			

Cashflow Statement (Half Yearly) Consolidated

(Subsidiary, Anondita Healthcare and Rubber Products India Ltd., w.e.f. 01/04/2024)


Figures In ₹ Lakhs, Margin In %, EPS in ₹

Cash Flow Statement (in ₹ Lakh)	H1 FY26	H1 FY25
Cash Flow from Operating Activity	-1,171.09	-1,589.45
Cash Flow from Investing Activity	-964.33	-1,678.95
Cash Flow from Financing Activity	5,735.45	3,300.81
Cash and Cash Equivalents at the Beginning of the Year	32.94	47.27
Cash and Cash Equivalents at the End of the Year	3,650.96	79.67


Financial Snapshot (Standalone)

Figures In ₹ Lakhs, Margin In %, EPS in ₹


Revenue from Operations




EBITDA — EBITDA Margin



PAT — PAT Margin



EPS



Income Statement (Half Yearly) Standalone

In ₹ Lakhs

Particulars	H1 FY26	H1 FY25	YoY Change
Revenue from operations	4765.06	2497.06	91%
Cost of Material Consumed	2166.28	1486.25	
Employee benefit expense	271.06	223.68	
Other Expenses	649.21	256.15	
Total	3086.55	1966.08	
EBITDA	1678.51	530.98	216%
EBITDA Margin (%)	35.23%	21.26%	452 bps
Depreciation and amortization expense	40.03	36.02	
EBIT	1638.48	494.96	231%
Financial costs	181.32	145.09	
Other Income	75.56	28.65	
PBT	1532.71	378.51	305%
Tax Expense			
Current Tax	370.65	78.74	
Deferred Tax	15.49	17.30	
PAT	1146.57	282.47	306%
Net Profit	1146.57	282.47	306%
Net Profit Margin (%)	24.06%	11.31%	486 bps
EPS (Diluted)	8.14	3.05	167%

Balance Sheet (Half Yearly) Standalone

In ₹ Lakhs

Equities and Liabilities	H1 FY26	H1 FY25	Assets	H1 FY26	H1 FY24
Shareholder's Funds			Non-current Assets		
Share Capital	1,808.66	886.24	Fixed Assets	1,275.48	1,246.15
Reserves & Surplus	7,963.81	1,077.21	Goodwill		
Minority Interest			Capital Work in progress	1,522.08	50.36
Total	9,772.47	1,963.45	Non Current Investment	351.58	351.58
Non-Current Liabilities			Deffered Tax Assets (Net)		
Lont Term Borrowings	1,370.40	1,320.65	Long Term Loans & Advances	37.66	37.66
Deferred Tax Liability	24.06	17.30	Other Non Current Assets	0.2	0.3
Long Term Provisions	15.13	7.51	Total Non-current Assets	3,187.00	1,686.05
Total Non-Current Liabilities	1,409.59	1,345.46	Current Assets		
Current Liabilities			Inventories	1,103.36	728.35
Short Term Borrowings	1,738.22	1,475.52	Trade Receivables	3,321.36	1,405.72
Trade Payables			Cash & Bank Balance	3,628.28	41.81
outstanding Dues of micro & small Enterprises	153.00	168.87	Short Term Loans & Advances	2,360.94	1,183.60
outstanding Dues of Creditors	323.64	118.65	Other Current Assets	731.45	228.97
Other Current Liabilities	265.97	123.45	Total Current Assets	11,145.39	3,588.45
Short Term Provisions	732.51	79.30	Total	14,332.39	5,274.50
Total Current Liabilities	3,213.34	1,965.79			
Total	14,332.39	5,274.50			

Cashflow Statement (Half Yearly) Standalone

In ₹ Lakhs

Cash Flow Statement (in ₹ Lakh)	H1 FY26	H1 FY25
Cash Flow from Operating Activity	(1,253.13)	(1,124.92)
Cash Flow from Investing Activity	(945.60)	(1,683.18)
Cash Flow from Financing Activity	5,801.45	2,846.92
Cash and Cash Equivalents at the Beginning of the Year	25.56	3.00
Cash and Cash Equivalents at the End of the Year	3,628.28	41.81

Historical Income Statement

In ₹ Lakhs

Particulars	Anondita Medicare Ltd (Consolidated)	Anondita Medicare Ltd. (Standalone)	Anondita Healthcare (Proprietorship)	
	FY25	FY25	FY24	FY23
(A) REVENUE				
Revenue from Operations	7,699.07	6051.52	4,643.21	3,591.49
Other Income	13.88	36.38	12.33	22.48
Total Revenue	7,712.95	6087.90	4,655.53	3,613.97
(B) EXPENSES				
Cost of Materials Consumed	3,376.69	3376.69	3,147.09	2,887.63
Purchase of Stock-in-Trade	744.86	-	-	-
Changes in Inventories of Finished Goods, WIP & Stock-in-Trade	(293.20)	(202.97)	56.96	(84.38)
Employee Benefit Expense	686.80	589.55	182.40	150.22
Finance Costs	291.09	289.46	340.61	270.97
Depreciation & Amortization Expense	75.79	91.54	65.66	62.57
Other Expenses	618.70	499.80	347.54	280.20
Total Expenses	5,500.72	4644.07	4,140.27	3,567.21
(D) Profit Before Tax	2,212.22	1443.84	515.26	46.76
(E) Tax Expense				
Current Tax	553.25	361.15	133.06	13.13
Deferred Tax	8.50	2.71	(2.26)	(1.06)
(F) PROFIT AFTER TAX	1,650.47	1079.98	384.47	34.69
Diluted	14.11	9.60	NA	NA

Historical Balance Sheet

In ₹ Lakhs

Particulars	Anondita Medicare Ltd (Consolidated)	Anondita Medicare Ltd. (Standalone)	Anondita Healthcare (Proprietorship)	
	FY25	FY25	FY24	FY23
(A) EQUITY AND LIABILITIES				
1. Shareholders' Funds				
(a) Share Capital	1,329.36	1,329.36	–	–
(b) Proprietor's Capital Balance	–	-	19.54	213.89
(c) Reserves & Surplus	2,457.58	1,505.40	1,039.25	654.78
(d) Minority Interest	118.16	-	–	–
Total Shareholders' Funds	3,905.10	2,834.76	1,058.79	868.68
2. Non-Current Liabilities				
(a) Long-term Borrowings	1,190.76	1,190.76	1,104.23	968.95
(b) Long-term Provisions	9.83	9.83	5.17	5.56
(c) Deferred Tax Liability	29.51	29.72	27.02	29.28
Total Non-Current Liabilities	1,230.10	1,230.31	1,136.42	1,003.79
3. Current Liabilities				
(a) Short-term Borrowings	1,548.34	1548.34	1,297.06	1,297.32
(b) Trade Payables	381.52	352.58	500.67	455.23
(c) Other Current Liabilities	210.06	134.74	90.34	79.67
(d) Short-term Provisions	551.86	326.76	208.23	75.30
Total Current Liabilities	2,691.79	2,362.43	2,096.30	1,907.52
TOTAL LIABILITIES	7,826.99	6,427.50	4,291.51	3,779.98

Historical Balance Sheet

In ₹ Lakhs

Particulars	Anondita Medicare Ltd (Consolidated)	Anondita Medicare Ltd. (Standalone)	Anondita Healthcare (Proprietorship)	
	FY25	FY25	FY24	FY23
B. ASSETS				
1. Non-Current Assets				
(a) Property, Plant & Equipment and Intangible Assets				
(i) Property, Plant & Equipment	1,333.20	1,331.31	1,014.13	1,035.19
(ii) Capital Work-in-Progress	649.61	649.61	359.73	–
(iii) Goodwill	19.18	-	–	–
Total PPE & Intangible Assets	2,001.99	1,980.92	1,373.86	1,035.19
(b) Long-term Investments	331.40	351.58	331.40	331.40
(c) Long-term Loans & Advances	37.66	37.66	101.92	120.25
(d) Other Non-current Assets	0.24	0.24	–	–
(e) Deferred Tax Assets	0.22	-	–	–
Total Non-Current Assets	369.52	389.48	433.32	451.65
2. Current Assets				
(a) Inventories	1,349.86	896.28	710.15	747.65
(b) Trade Receivables	2,675.33	1,660.42	1,248.27	1,314.62
(c) Cash & Cash Equivalents	32.94	25.56	26.72	25.95
(d) Short-term Loans & Advances	1,185.37	1,384.76	386.60	96.79
(e) Other Current Assets	211.94	90.06	112.60	108.13
Total Current Assets	5,455.48	4,057.10	2,484.33	2,293.14
TOTAL ASSETS	7,826.99	6,427.50	4,291.51	3,779.98

Historical Cashflow Statement

In ₹ Lakhs

Cash Flow Statement (in ₹ Lakh)	Anondita Medicare Ltd (Consolidated)	Anondita Medicare Ltd. (Standalone)	Anondita Healthcare (Proprietorship)	
	FY25	FY25	FY24	FY23
Cash Flow from Operating Activity	-1046.59	607.96	1054.88	-949.63
Cash Flow from Investing Activity	-2290.97	(2292.89)	-654.17	-25.34
Cash Flow from Financing Activity	3323.23	1707.49	-399.95	990.72
Cash and Cash Equivalents at the Beginning of the Year	47.27	3.00	25.95	10.20
Cash and Cash Equivalents at the End of the Year	32.94	25.56	26.72	25.95

Expanding Global Reach

- Anondita Medicare Ltd. has obtained the SABS licence from the South African Bureau of Standards, confirming compliance with national and international quality, safety, and performance standards. The Company has been shortlisted for South African government supplies and is in the process of finalising the agreement.
- The Company has entered into an agreement with a reputed overseas partner in Kenya for the supply of its owned brand, “Cobra.” Trial orders have been received, marking the beginning of its international expansion.
- With a strong focus on innovation and excellence, the Company aims to broaden its product portfolio, expand its footprint in domestic and global markets, and establish itself as a trusted name in global healthcare.

Strategy Going Forward

UN Qualification and Export Launch

- The Company is applying for UNFPA Pre-qualification for its female condom products to participate in international public health procurement programs.
- To ensure the highest quality and compliance for international markets, the company is currently undergoing the process of obtaining a UN license.
- This prestigious qualification will pave the way for a targeted export launch by the end of the current financial year or the first quarter of the next.

Goal for FY26

Increase production capacity

Develop innovative contraceptives

Implement sustainable practices

Launch community education programs

Export to Brazil and South American countries

To increase our market share in condom industry

Expand distribution channels

Develop robust quality control

Advocate for policy changes

THANK YOU

